International Clinical Trial: A Study of DS-3939a in Participants With Solid Tumors

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739966) titled 'A Study of DS-3939a in Participants With Solid Tumors' on July 28.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Daiichi Sankyo

Condition: Solid Tumor Locally Advanced Non-Small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer

Intervention: Drug: DS-3939a Drug: Pembrolizumab Drug: Carboplatin Drug: Pemetrexed

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: October 1, 2026

Target Sample Size: 400

To know more, visit https://clin...